Article Text

This article has a correction. Please see:

Download PDFPDF
Tailoring the length of antiviral treatment for hepatitis C
  1. Alessandra Mangia1,
  2. Angelo Andriulli2
  1. 1
    Liver Unit
  2. 2
    Division of Gastroenterology, IRCCS, “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy
  1. Correspondence to Dr Alessandra Mangia, Liver Unit, IRCCS “Casa Sollievo della Sofferenza” Hospital, 71013 San Giovanni Rotondo, Italy; a.mangia{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The effectiveness of interferon in blocking the replication of hepatitis C virus (HCV) in infected cells is enhanced in patients with genotypes 2 and 3 as compared to genotype 1.1 2 The clinical counterpart of these experimental observations is the higher rate of viral clearance in easy-to-cure genotypes, as reported in registration trials on Peg-Interferon (Peg-IFN) and ribavirin therapy.3 4 5 Consequently, so far, HCV genotyping has represented the common approach to tailoring drug dosage and length of therapy. Recently, an innovative concept has emerged which might also govern treatment schedules besides HCV genotypes: in response to a single interferon injection, viral decline in blood differs not only among individual genotypes but also from patient to patient infected by the same viral strain.6 7 8 This evidence has led to the claim that patients with prompt response could benefit from a shorter duration of treatment compared to that which is currently recommended, whereas for slower responders a prolonged course of treatment might be needed to maximise virological response.

How to categorise rapid, slow or null responders according to current antiviral therapy is a matter of intensive investigation.9 10 Past experience has corroborated the usefulness of evaluating serum HCV-RNA at treatment weeks 4, 12 and 24: rapid responders are patients who are non-viraemic at week 4, and non-responders are those still viraemic at week 24; all other patients falling between these two extremes are defined as slow responders.11 12 As the timing and magnitude of virological response are highly variable from one patient to another, slow responders might include several subgroups of patients with differing chances of achieving a sustained virological response (SVR). Indeed, if a subset of patients defined as complete early virological responders shows an absence of HCV-RNA at treatment week 12, it is …

View Full Text


  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and British Society of Gastroenterology